Bio-Techne Corporation (TECH) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $55.17 (-0.27%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 12, 2025 | Justin Bowers | Deutsche Bank | $72.00 | +30.5% |
| Sep 2, 2025 | Conor McNamara | RBC Capital | $73.00 | +32.3% |
| Oct 31, 2024 | Catherine Schulte | Robert W. Baird | $84.00 | +52.3% |
| Oct 30, 2024 | Paul Knight | KeyBanc | $80.00 | +45.0% |
| Aug 16, 2024 | Sung Ji Nam | Scotiabank | $83.00 | +50.4% |
| May 5, 2022 | Paul Knight | KeyBanc | $125.00 | +126.6% |
| May 6, 2021 | Patrick B Donnelly | Citigroup | $106.25 | +92.6% |
Top Analysts Covering TECH
TECH vs Sector & Market
| Metric | TECH | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.12 | 2.24 | 2.41 |
| Analyst Count | 8 | 8 | 18 |
| Target Upside | +25.7% | +1150.2% | +14.9% |
| P/E Ratio | 108.18 | 6.77 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $1.21B | $1.22B | $1.23B | 10 |
| 2026-09-30 | $292M | $298M | $304M | 4 |
| 2026-12-31 | $308M | $314M | $320M | 7 |
| 2027-03-31 | $332M | $340M | $346M | 4 |
| 2027-06-30 | $342M | $349M | $355M | 6 |
| 2027-09-30 | $309M | $316M | $322M | 4 |
| 2027-12-31 | $328M | $335M | $341M | 7 |
| 2028-03-31 | $351M | $359M | $365M | 3 |
| 2028-06-30 | $367M | $375M | $382M | 5 |
| 2029-06-30 | $1.51B | $1.53B | $1.55B | 2 |
| 2030-06-30 | $1.69B | $1.71B | $1.73B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $1.94 | $1.98 | $2.05 | 8 |
| 2026-09-30 | $0.45 | $0.46 | $0.47 | 3 |
| 2026-12-31 | $0.49 | $0.51 | $0.52 | 6 |
| 2027-03-31 | $0.58 | $0.60 | $0.61 | 3 |
| 2027-06-30 | $0.61 | $0.62 | $0.64 | 5 |
| 2027-09-30 | $0.50 | $0.52 | $0.53 | 3 |
| 2027-12-31 | $0.58 | $0.59 | $0.61 | 6 |
| 2028-03-31 | $0.66 | $0.68 | $0.70 | 4 |
| 2028-06-30 | $0.66 | $0.68 | $0.70 | 6 |
| 2029-06-30 | $2.98 | $3.03 | $3.08 | 1 |
| 2030-06-30 | $3.10 | $3.15 | $3.20 | 1 |
Frequently Asked Questions
What is the analyst consensus for TECH?
The consensus among 8 analysts covering Bio-Techne Corporation (TECH) is Buy with an average price target of $69.33.
What is the highest price target for TECH?
The highest price target for TECH is $125.00, set by Paul Knight at KeyBanc on 2022-05-05.
What is the lowest price target for TECH?
The lowest price target for TECH is $72.00, set by Justin Bowers at Deutsche Bank on 2025-12-12.
How many analysts cover TECH?
8 analysts have issued ratings for Bio-Techne Corporation in the past 12 months.
Is TECH a buy or sell right now?
Based on 8 analyst ratings, TECH has a consensus rating of Buy (2.12/5) with a +25.7% upside to the consensus target of $69.33.
What are the earnings estimates for TECH?
Analysts estimate TECH will report EPS of $1.98 for the period ending 2026-06-30, with revenue estimated at $1.22B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.